NINTEDANIB

Drug Boehringer Ingelheim International GmbH
Total Payments
$37,081
Transactions
22
Doctors
14
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2020 $7,517 6 2
2019 $29,564 16 14

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $27,962 12 75.4%
Travel and Lodging $9,119 10 24.6%

Top Doctors Receiving Payments for NINTEDANIB

Doctor Specialty Location Total Records
, MD Internal Medicine Ann Arbor, MI $8,396 3
, MD Pulmonary Disease Charlottesville, VA $6,987 4
Walter Baile Houston, TX $4,276 1
, M.D Rheumatology Cleveland, OH $3,124 4
, MD Internal Medicine Los Angeles, CA $3,000 1
, MD Rheumatology Farmington, CT $2,500 1
, MD Internal Medicine Ann Arbor, MI $2,400 1
, MD Pulmonary Disease Richmond, VA $2,400 1
, M.D Family Medicine Santa Ana, CA $1,741 1
, MD Anesthesiology Bend, OR $829.40 1
, M.D Rheumatology Houston, TX $629.17 1
, M.D Pulmonary Disease Lebanon, NH $619.68 1
, MD Internal Medicine Chicago, IL $142.20 1
, MD Internal Medicine Palo Alto, CA $37.00 1

About NINTEDANIB

NINTEDANIB is a drug associated with $37,081 in payments to 14 healthcare providers, recorded across 22 transactions in the CMS Open Payments database. The primary manufacturer is Boehringer Ingelheim International GmbH.

Payment data is available from 2019 to 2020. In 2020, $7,517 was paid across 6 transactions to 2 doctors.

The most common payment nature for NINTEDANIB is "Consulting Fee" ($27,962, 75.4% of total).